- Rosuvastatin in patients with HIV at moderate cardiovascular risk did not alter atherosclerosis progression vs placebo at 96 weeks.
- Drug yielded predictable effects on total and low-density lipoprotein cholesterol (LDL-C).
Why this matters
- Risk scores for myocardial infarction lack sensitivity and specificity in people with HIV.
- Benefits of statin therapy in patients with HIV at low-moderate risk may not justify the potential harms.
- No difference seen between placebo and treatment groups in progression of intima-media thickness from baseline to 96 weeks at any site (all P>.05).
- More adverse events in the treatment group.
- Expected effects seen for total cholesterol and LDL-C: mean change −1.06 mmol/L with drug vs −0.06 mmol/L with placebo; P<.0001.>
- Randomized, double-blinded, placebo-controlled, multinational trial comparing placebo and rosuvastatin for 96 weeks in people with HIV (stable antiretroviral regimen >3 months; viral load
- Participants were randomly allocated 1:1 (stratified by site) to 20 mg/day rosuvastatin or matched placebo.
- Outcome: atherosclerotic progression (estimated by change in carotid intima-media thickness).
- Results were presented without peer review at a conference.